Literature DB >> 9037063

CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2.

E N Tsitsikov1, D A Wright, R S Geha.   

Abstract

CD30 is a member of the tumor necrosis factor receptor (TNFR) superfamily expressed on activated T and B lymphocytes and natural killer cells. Ligation of CD30 was previously shown to induce NF-kappaB activation and HIV expression in chronically infected T lymphocytes. In this study, we report that two members of the TNFR-associated factor (TRAF) family of proteins, TRAF1 and TRAF2, independently bind to the intracellular domain of CD30 (CD30IC). Transient overexpression of TRAF2, but not TRAF1, induced NF-kappaB activation and HIV-1-long terminal repeat-driven transcription in the T cell line, KT3. Moreover, dominant negative mutants consisting of the TRAF domain of TRAF1 and TRAF2 inhibited CD30 induction of NF-kappaB activation and HIV-1 transcription. These results suggest that CD30 ligation may enhance the expression of HIV via TRAF-2-mediated activation of NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9037063      PMCID: PMC19801          DOI: 10.1073/pnas.94.4.1390

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation.

Authors:  G Cheng; D Baltimore
Journal:  Genes Dev       Date:  1996-04-15       Impact factor: 11.361

2.  CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity.

Authors:  M Alzona; H M Jäck; R I Fisher; T M Ellis
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

3.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

4.  Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines.

Authors:  P Froese; H Lemke; J Gerdes; B Havsteen; R Schwarting; H Hansen; H Stein
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

5.  CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins.

Authors:  R W Gedrich; M C Gilfillan; C S Duckett; J L Van Dongen; C B Thompson
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

6.  TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor.

Authors:  H Nakano; H Oshima; W Chung; L Williams-Abbott; C F Ware; H Yagita; K Okumura
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

7.  Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines.

Authors:  G Del Prete; M De Carli; F Almerigogna; C K Daniel; M M D'Elios; G Zancuoghi; F Vinante; G Pizzolo; S Romagnani
Journal:  FASEB J       Date:  1995-01       Impact factor: 5.191

8.  The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription.

Authors:  A V Tsytsykova; E N Tsitsikov; R S Geha
Journal:  J Biol Chem       Date:  1996-02-16       Impact factor: 5.157

9.  An established CD4+ T lymphoma cell line derived from a patient with so-called Lennert's lymphoma: possible roles of cytokines in histopathogenesis.

Authors:  S Shimizu; T Takiguchi; S Sugai; M Matsuoka; S Konda
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

10.  CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection.

Authors:  R Manetti; F Annunziato; R Biagiotti; M G Giudizi; M P Piccinni; L Giannarini; S Sampognaro; P Parronchi; F Vinante; G Pizzolo; E Maggi; S Romagnani
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  10 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.

Authors:  E J Croager; A M Gout; L J Abraham
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

3.  Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.

Authors:  Chia-Ching Wang; Cassandra Thanh; Erica A Gibson; Maya Ball-Burack; Louise E Hogan; Benjamin Descours; Norman Jones; Alexander B Carvidi; Sadie Munter; Sonia Bakkour; Michael P Busch; Jeffrey M Milush; Steven G Deeks; Timothy J Henrich
Journal:  Blood Adv       Date:  2018-12-11

4.  Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption.

Authors:  Cecilia A Prator; Cassandra Thanh; Shreya Kumar; Tony Pan; Michael J Peluso; Ronald Bosch; Norman Jones; Jeffrey M Milush; Sonia Bakkour; Mars Stone; Michael P Busch; Steven G Deeks; Peter W Hunt; Timothy J Henrich
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

5.  Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule.

Authors:  O Gires; U Zimber-Strobl; R Gonnella; M Ueffing; G Marschall; R Zeidler; D Pich; W Hammerschmidt
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

6.  CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival.

Authors:  C S Duckett; C B Thompson
Journal:  Genes Dev       Date:  1997-11-01       Impact factor: 11.361

7.  Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.

Authors:  E Kilger; A Kieser; M Baumann; W Hammerschmidt
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

Review 8.  TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?

Authors:  Amit Kumar; Wasim Abbas; Georges Herbein
Journal:  Mediators Inflamm       Date:  2013-12-19       Impact factor: 4.711

9.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Authors:  Timothy J Henrich; Hiroyu Hatano; Oliver Bacon; Louise E Hogan; Rachel Rutishauser; Alison Hill; Mary F Kearney; Elizabeth M Anderson; Susan P Buchbinder; Stephanie E Cohen; Mohamed Abdel-Mohsen; Christopher W Pohlmeyer; Remi Fromentin; Rebecca Hoh; Albert Y Liu; Joseph M McCune; Jonathan Spindler; Kelly Metcalf-Pate; Kristen S Hobbs; Cassandra Thanh; Erica A Gibson; Daniel R Kuritzkes; Robert F Siliciano; Richard W Price; Douglas D Richman; Nicolas Chomont; Janet D Siliciano; John W Mellors; Steven A Yukl; Joel N Blankson; Teri Liegler; Steven G Deeks
Journal:  PLoS Med       Date:  2017-11-07       Impact factor: 11.069

10.  Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30.

Authors:  Louise E Hogan; Joshua Vasquez; Kristen S Hobbs; Emily Hanhauser; Brandon Aguilar-Rodriguez; Rajaa Hussien; Cassandra Thanh; Erica A Gibson; Alexander B Carvidi; Louis C B Smith; Shahzada Khan; Martin Trapecar; Shomyseh Sanjabi; Ma Somsouk; Cheryl A Stoddart; Daniel R Kuritzkes; Steven G Deeks; Timothy J Henrich
Journal:  PLoS Pathog       Date:  2018-02-22       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.